Senior FDA officials announced at the 2026 Aging Research and Drug Discovery Meeting that aging and longevity will be included in the agency's forthcoming Focus Areas of Regulatory Science update, targeted for fiscal year 2027. Panelists outlined plausible approval pathways for gerotherapeutics, including evidence across multiple age-related conditions or measured slowing of decline in intrinsic capacity. The discussion marks the first substantive regulatory articulation of how a drug might earn a broad aging indication.
Key Points
- Aging enters FDA regulatory science focus areas, targeted fiscal year 2027
- Approval may hinge on multi-condition benefit or intrinsic capacity decline
- Biomarkers need validation as surrogate endpoints, not merely prognostic markers
Longevity Analysis
A regulatory pathway for aging reframes interventions that currently sit outside clinical medicine as candidates for formal evaluation, with the burden shifting to measurable change across physical and mental capacity rather than a single disease endpoint. Intrinsic capacity as a trial construct is essentially a composite read on how well movement, cognition, cardiovascular reserve, and regenerative capacity hold together over time — the same signals that inform individual decision-making long before a drug exists. The demanding benefit–risk calculation for decades of treatment in low-risk populations underscores why removing sources of accelerated decline and tracking function consistently remain the higher-yield starting points.
Original published by LifeSpan.io, by Arkadi Mazin.